WELCOME
In hospital neonatal care, NeoDuoFlo® stands out — a dual-lumen orogastric feeding and decompression tube dedicated to safer, clinically informed support for neonatal patients.
Our device is aiming to transform neonatal care by reducing feeding complications, easing clinical workflows, and improving care outcomes for tiny fighters everywhere.
ABOUT US
Founded by professionals in neonatal care
NeoDuoFlo® was founded by neonatal care professionals from Queensland’s leading children’s hospitals who identified the critical need for a safer, more efficient neonatal feeding tube.
We’re an Australian-based, female-owned organisation, motivated by a mission that’s close to our own hearts; improving outcomes for preterm and critically ill babies by developing innovative, clinically driven medical devices. With deep clinical insight and cutting-edge design, NeoDuoFlo® is redefining neonatal care standards.
OUR PRODUCT AND TECHNOLOGY
Reducing the need for multiple interventions
Prioritises safety, comfort, and ease of use for healthcare providers, helping to prevent complications like feeding intolerance and aspiration.
Our dual-lumen design allows simultaneous feeding and gastric decompression, reducing the need for multiple interventions.
Crafted with biocompatible materials in a compact, easy-to-insert configuration, NeoDuoFlo® addresses the unique physiological needs of neonates.
HOW WE HELP
For practitioners
NeoDuoFlo® streamlines neonatal feeding protocols, allowing nurses and doctors to provide consistent, effective care with less disruption.
HOW WE HELP
For parents
We understand how vital safe feeding is to your baby’s health and comfort. NeoDuoFlo® is designed with your child’s safety in mind, providing gentle, effective feeding and decompression support.
DEVELOPMENT PROGRESS
Key milestones
AUGUST 2026
Manufacturing prototypes built by an ISO 13485-certified contract manufacturer, advancing the technology beyond proof of concept.
DECEMBER 2026
Planned neonatal preclinical study ahead of first-in-human studies.
JUNE 2026
Completed independent bench testing with the Medical Device Partnering Program at Flinders University.
SEPTEMBER 2026
PCT international patent application filed, building on two Australian provisional patents. Australian trade mark registered, with a Madrid Protocol application.
2027
First planned
in-human studies.
SUBSCRIBE FOR
News & updates
Keep up with our progress, including key milestones, study results, and neonatal news. Join us in setting a new gold standard for safer, innovative neonatal care.
AWARDS AND
Recognition
-
Stanford Biodesign Impact1 Innovators Forum and an invitation to the Impact1 Pediatric CEO Summit at Stanford in October 2026
-
Winner of the QUT BridgeTech Pitch Event
-
Winner of the ANFF-C and In-House Ventures pitch night
-
ANFF-C Gate 1 funding secured
-
Selected for the BEDA MedTech Accelerator at J.P. Morgan Healthcare Week in January 2027
-
AusBiotech Industry Growth Program.
